Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biogen (BIIB) PT Lowered to $290 at Needham & Company
February 4, 2022 6:26 AM ESTNeedham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $292.00) while maintaining a Buy rating.
The analyst commented, "BIIB pulled back ~2% following lower-than-expected 2022 guidance as we await visibility into Aduhelm's final coverage decision in April. Irrespective, it... More
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM ESTStifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.
The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More
Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets
February 3, 2022 8:17 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $260.00 price target on Biogen (NASDAQ: BIIB), following the company's Q4 earnings report.
The analyst quotes: "Guidance represents a challenging set up for 2022with expenses still too high by our view, and not... More
